Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis

Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out on top—at least for now.